selected publications
-
Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2020
Academic Article
GET IT
Times cited: 1 -
Accelerated single cell seeding in relapsed multiple myeloma.
Nature communications.
2020
Academic Article
GET IT
Times cited: 29 -
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2020
Academic Article
GET IT
Times cited: 5 -
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2019
Academic Article
GET IT
Times cited: 7 -
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.
Leukemia & lymphoma.
2018
Letter
GET IT
Times cited: 14 -
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2017
Academic Article
GET IT
Times cited: 26 -
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.
Leukemia & lymphoma.
2017
Letter
GET IT
Times cited: 2 -
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
Leukemia & lymphoma.
2017
Academic Article
GET IT
Times cited: 41 -
Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.
Cancer immunology research.
2016
Academic Article
GET IT
Times cited: 28 -
Proteomic profiling in plasma cell disorders: a feasibility study.
Leukemia & lymphoma.
2016
Letter
GET IT
Times cited: 6 -
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.
Leukemia & lymphoma.
2016
Academic Article
GET IT
Times cited: 8 -
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.
Clinical biochemistry.
2016
Academic Article
GET IT
Times cited: 41 -
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
Blood.
2016
Letter
GET IT
Times cited: 12 -
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
Leukemia & lymphoma.
2016
Academic Article
GET IT
Times cited: 3 -
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.
Bone marrow transplantation.
2016
Academic Article
GET IT
Times cited: 34 -
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.
Cancer immunology research.
2015
Academic Article
GET IT
Times cited: 126 -
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2015
Academic Article
GET IT
Times cited: 22 -
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Blood.
2014
Academic Article
GET IT
Times cited: 69 -
Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy.
Journal of translational medicine.
2013
Academic Article
GET IT
Times cited: 16 -
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
Leukemia.
2013
Letter
GET IT
Times cited: 13 -
Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.
Blood.
2012
Academic Article
GET IT
Times cited: 40 -
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 63 -
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.
Blood.
2009
Academic Article
GET IT
Times cited: 215